What’s being cut at NIH

A look at the government’s far-reaching rollback in research grants so far.

By Meagan Parrish • April 25, 2025

Trump reveals pharma reform priorities in drug pricing executive order

The order takes aim at fixing the IRA’s “pill penalty,” as well as PBM reform and other attempts to lower drug prices.  

By Amy Baxter • April 23, 2025

Explore the Trendline➔

Rare diseases

As drug developers find promise in the rare diseases, deals and treatments are on the rise

By PharmaVoice staff

How a scrapped Pfizer drug became a winner for SpringWorks

SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.

By Alexandra Pecci • April 21, 2025

A big moment is coming for psychedelics

Compass Pathways expects to publish the first phase 3 results from a large-scale, psilocybin drug trial by the end of this quarter.

By Meagan Parrish • April 18, 2025

HHS layoffs may be illegal, legal experts say

The federal health department sidestepped normal procedures as it laid off 10,000 employees, according to sources. One union has already filed an internal complaint, while at least two law firms are exploring suits.

By Rebecca Pifer • April 17, 2025

Novartis scores NFL deal to tackle health outcomes

The non-traditional marketing approach comes amid a potential crackdown on TV drug ads. 

By Amy Baxter • April 17, 2025

The fallout from UnitedHealth’s CEO slaying

Brian Thompson’s murder has raised questions about the cost of U.S. healthcare, embroiling insurers, drugmakers and PBMs in a battle for the future of the industry.

By PharmaVoice staff • April 15, 2025

‘Chaos’ in the biotech market has dampened hopes of a rebound. What does that mean for dealmaking and IPOs?

The biotech market is taking a beating amid Trump’s turbulent economic policies.

By Amy Baxter • April 15, 2025

Pharma’s capital allocation could shift as tariffs threaten an already fragile profit model

Major changes to the dynamics of the pharmaceutical ecosystem are making executive decisions even tougher.

By Michael Gibney • April 14, 2025

Pharma’s US manufacturing moment: Where companies are making the biggest moves

The tariff war has prompted new calls to reshore manufacturing. Several large pharmas have already made the leap.

By Meagan Parrish • April 11, 2025

Trump’s tariff tirade and sudden calm keep Big Pharma on its toes

A wild ride in an escalating trade war has torn at Big Pharma’s shares while global markets flag in the back-and-forth winds.

By Michael Gibney • April 10, 2025

US risks losing biotech edge to China, report warns

“There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S. to invest at least $15 billion into the sector over the next five years.

By Ned Pagliarulo • April 9, 2025

US vs. EU: When it comes to novel Alzheimer’s drugs, regulators can’t seem to agree

The FDA is much more flexible in approving first-in-class drugs compared to European regulators.  

By Amy Baxter • April 7, 2025

Dr. Oz confirmed to lead CMS

Dr. Mehmet Oz, a physician and TV personality, will lead the agency during a turbulent time for federal health programs as the HHS lays off thousands of staffers and Republicans float potential cuts to Medicaid.

By Emily Olsen • April 4, 2025

Industry leaders react to HHS being ‘reduced to a shell’

What healthcare watchdogs have said about the far-reaching job cuts this week.

By Meagan Parrish and Amy Baxter • April 3, 2025

With government health info in limbo, drugmakers lose credible sources

The lack of clear communication from the government could spark wide-ranging issues in pharma — from sowing confusion about clinical trial design to further eroding public trust.

By Alexandra Pecci • April 1, 2025

FDA’s ‘mixed signals’ on diversity have entangled clinical trials. Here’s how pharma can push ahead.

The agency is still unclear about where it will stand on clinical trial diversity, but companies are looking for answers and leaning toward good science.

By Meagan Parrish • March 28, 2025

HHS announces sweeping reorganization, including cuts of 10K workers

Along with shrinking the HHS’ workforce further, the reorganization announced Thursday will cut the department from 28 divisions to 15, and close five regional offices.

By Rebecca Pifer • March 27, 2025

Rx-to-OTC rule gets pushed back — again

A delay of the prescription-to-OTC rule signals health agencies’ ongoing reluctance to implement new regulations.

By Amy Baxter • March 26, 2025

Lilly, Novo expand DTC reach of obesity meds after compound win

The FDA delisted semaglutide and tirzepatide from its shortage list, putting an end to copycat GLP-1s.

By Amy Baxter • March 24, 2025

How pharma could feel the pain of a recession

Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.

By Meagan Parrish • March 21, 2025

Vaccine makers face mRNA backlash as states seek further restrictions

A handful of states are targeting the technology at the same time the Trump administration is cutting research funding and revoking vaccine contracts.

By Amy Baxter • March 19, 2025

The key factors shaping China’s biopharma boom

Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.

By Alexandra Pecci • March 19, 2025

Lawmakers tease out pharma’s influence over RFK Jr. through probe into Mar-a-Lago meetings

HHS head Robert F. Kennedy Jr. has long been an opponent of pharma influence in government. U.S. lawmakers are asking whether unofficial Mar-a-Lago meetings point to a change of heart.

By Michael Gibney • March 13, 2025

IRA reforms, including a small molecule fix, could be on the table. Will Trump and the GOP make the leap?

Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.

By Amy Baxter • March 12, 2025